Literature DB >> 228594

RMI 15,731 (1-[5-tetradecyloxy-2-furanyl]-ethanone), a new antirhinovirus compound.

R J Ash, R A Parker, A C Hagan, G D Mayer.   

Abstract

RMI 15,731 (1-[5-tetradecyloxy-2-furanyl]-ethanone) is a new antiviral compound with activity specific for rhinoviruses. Virus synthesis in R-HeLa cells was susceptible to low concentrations (0.25 micrograms/ml) of the compound. RMI 15,731 was effective if added for 1 h before infection and removed or if added as late as 6 h postinfection. Low concentrations of the compound directly inactivated infectious rhinovirus in a time- and temperature-dependent fashion. RMI 15,731 appears to be a promising new antirhinovirus compound for clinical evaluation since it (i) blocks intracellular virus synthesis (without cellular toxicity), and (ii) directly inactivates virions. The last property may be important in limiting virus shedding from an infected host.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 228594      PMCID: PMC352850          DOI: 10.1128/AAC.16.3.301

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  3 in total

1.  Measurement of cell growth in tissue culture with a phenol reagent (folin-ciocalteau).

Authors:  V I OYAMA; H EAGLE
Journal:  Proc Soc Exp Biol Med       Date:  1956-02

Review 2.  Rhinoviruses.

Authors:  E J Stott; R A Killington
Journal:  Annu Rev Microbiol       Date:  1972       Impact factor: 15.500

3.  Effect of magnesium on replication of rhinovirus HGP.

Authors:  M Fiala; G E Kenny
Journal:  J Virol       Date:  1967-06       Impact factor: 5.103

  3 in total
  7 in total

1.  Two groups of rhinoviruses revealed by a panel of antiviral compounds present sequence divergence and differential pathogenicity.

Authors:  K Andries; B Dewindt; J Snoeks; L Wouters; H Moereels; P J Lewi; P A Janssen
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

2.  Lack of quantitative correlation between inhibition of replication of rhinoviruses by an antiviral drug and their stabilization.

Authors:  K Andries; B Dewindt; J Snoeks; R Willebrords
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

3.  Comparative studies on the modes of action of the antirhinovirus agents Ro 09-0410, Ro 09-0179, RMI-15,731, 4',6-dichloroflavan, and enviroxime.

Authors:  Y Ninomiya; M Aoyama; I Umeda; Y Suhara; H Ishitsuka
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

Review 4.  Chemotherapy of rhinovirus colds.

Authors:  S J Sperber; F G Hayden
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

5.  Antirhinovirus compound 44,081 R.P. inhibits virus uncoating.

Authors:  B Alarcon; A Zerial; C Dupiol; L Carrasco
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

6.  Antirhinovirus activity of purine nucleoside analogs.

Authors:  E De Clercq; R Bernaerts; D E Bergstrom; M J Robins; J A Montgomery; A Holy
Journal:  Antimicrob Agents Chemother       Date:  1986-03       Impact factor: 5.191

Review 7.  Picornavirus inhibitors.

Authors:  L Carrasco
Journal:  Pharmacol Ther       Date:  1994       Impact factor: 12.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.